Equities research analysts expect that Galectin Therapeutics Inc. (NASDAQ:GALT – Get Rating) will announce earnings of ($0.10) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Galectin Therapeutics’ earnings. Galectin Therapeutics posted earnings per share of ($0.11) during the same quarter last year, which indicates a positive year over year growth rate of 9.1%. The firm is expected to issue its next quarterly earnings report on Monday, January 1st.
According to Zacks, analysts expect that Galectin Therapeutics will report full year earnings of ($0.42) per share for the current fiscal year. For the next fiscal year, analysts expect that the business will post earnings of ($0.42) per share. Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for Galectin Therapeutics.
Galectin Therapeutics (NASDAQ:GALT – Get Rating) last posted its earnings results on Thursday, March 31st. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.07.
Galectin Therapeutics stock opened at $1.74 on Wednesday. The firm has a market cap of $103.25 million, a price-to-earnings ratio of -3.35 and a beta of 1.72. Galectin Therapeutics has a 52 week low of $1.50 and a 52 week high of $5.70. The business’s 50-day moving average price is $1.81 and its 200 day moving average price is $2.36. The company has a quick ratio of 4.63, a current ratio of 4.63 and a debt-to-equity ratio of 79.37.
A number of institutional investors and hedge funds have recently modified their holdings of GALT. BlackRock Inc. lifted its position in shares of Galectin Therapeutics by 0.7% in the fourth quarter. BlackRock Inc. now owns 793,025 shares of the company’s stock valued at $1,642,000 after acquiring an additional 5,443 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Galectin Therapeutics by 3.5% in the fourth quarter. Geode Capital Management LLC now owns 559,728 shares of the company’s stock valued at $1,158,000 after buying an additional 18,862 shares in the last quarter. Millennium Management LLC grew its stake in shares of Galectin Therapeutics by 15.8% in the fourth quarter. Millennium Management LLC now owns 405,601 shares of the company’s stock valued at $840,000 after buying an additional 55,265 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of Galectin Therapeutics by 2,033.5% in the fourth quarter. Renaissance Technologies LLC now owns 215,400 shares of the company’s stock valued at $446,000 after buying an additional 205,304 shares in the last quarter. Finally, Keybank National Association OH acquired a new stake in shares of Galectin Therapeutics in the third quarter valued at $388,000. 12.25% of the stock is currently owned by institutional investors.
About Galectin Therapeutics (Get Rating)
Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.
- Get a free copy of the StockNews.com research report on Galectin Therapeutics (GALT)
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
- Top 3 Safe Stocks for Conservative Investors
- UiPath Stock is Nearing Rock Bottom Down Here
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.